BlueYard Capital’s Post

If TB programs continue to use century-old tools like microscopy, we will never detect drug-resistance It is time to replace microscopy with WHO-endorsed rapid molecular diagnostics! https://lnkd.in/eVgyFfNz

Thank you, Madhukar Pai, for your insightful article. Building on your work, I would like to delve into some thought-provoking points from the study "Transforming Tuberculosis Diagnosis." Transforming tuberculosis diagnosis (nature.com) In my view, the most critical objective for manufacturers should be to advance multi-disease testing to replace the traditional single-disease approach. As you noted, single-disease testing has its limitations because patients often present with a range of symptoms, not isolated diseases. This means that ruling out one condition doesn’t guarantee effective treatment for another. With multi-morbidity being so prevalent, multi-disease testing presents a viable solution. Another crucial takeaway from your article is the potential of molecular testing to detect multiple infectious diseases simultaneously. This capability could allow for a broader array of tests to be conducted in tandem, streamlining the diagnostic process. Moreover, when samples are easy to collect, coupled with the user-friendliness of the operating platform, healthcare providers are more inclined to perform these diagnostic tests. We also need to prioritize affordable tests to replace the costly options currently available, without compromising performance. Advocating for molecular testing and decentralized point-of-care (POC) solutions could facilitate quicker diagnoses and informed treatment decisions right from the first patient consultation. For decentralized point-of-care testing to effectively complement centralized lab-based testing, the design must be guided by a comprehensive framework that ensures competence, consistency, and reliability in testing processes. This approach is essential for maintaining the quality and accuracy of results, ensuring patient safety, and meeting regulatory requirements and accreditation standards. Additionally, given the critical importance of seamless integration of test results into electronic health records (EHRs) and other clinical systems, the device must include provisions for POCT1-A connectivity. Finally, I wholeheartedly agree with your perspective: “A simple, non-sputum sample, combined with affordable, multi-disease POC molecular technology deployed in decentralized settings, would reach a much larger population, close the case detection gap, and curb TB transmission at the population level.” The future lies in syndromic testing, leveraging advanced molecular point-of-care solutions. Let's all work towards that vision! Alvin Wei Edward L.

I was deeply impressed by the rigor and thoroughness demonstrated in this remarkable study. The meticulous approach to elucidate the molecular mechanisms of AAV6 under light stress provides significant insights into oxidative modifications and DNA damage and establishes a clear and actionable pathway toward improving capsid design and stabilization strategies. This clarity of purpose and precision is truly inspiring. As someone who had the privilege of being trained in the same lab, I recognize that the commitment to rigor and detail exemplified in this work forms a shared foundation that continues to guide my research approach. During my time in the lab, the emphasis on precision and methodical problem-solving shaped my perspective on scientific inquiry, and it is profoundly gratifying to see this legacy being carried forward and expanded upon in such impactful ways. Advancements in computational tools, such as AlphaFold3 for structural prediction and molecular dynamics simulations, could complement these experimental findings. When combined with approaches like density functional theory (DFT) to estimate energy levels for oxidative reactions, these tools could provide even deeper insights into structural dynamics under light-induced stress, further enhancing capsid stability and efficiency. This work reflects the excellence of the research group and highlights the enduring impact of a shared academic ethos. Witnessing how these foundational values drive innovation and progress in gene therapy research is truly exciting. I eagerly look forward to seeing the far-reaching contributions this research will bring to the field and beyond. 😁 #GeneTherapy #AAVVectors #MolecularBiology #StructuralBiology #ComputationalBiology #ResearchCulture

I'd like to share our recent publication on the photo-stability of AAV6. Methods used were; PCR for titer AUC for particle size distribution CE for VP (SDS) and DNA Intact LC-MS and LC-MS/MS for VP structural analysis Microscopy for biological assay (GFP expression) D65 light (ICH guideline light stress) resulted in marked decrease in biological activity because of multiple causes. DNA degradation (like formation of cyclobutane pyrimidine dimers) and VP oxidation. Aggregation was also occurred which was indirectly detected by AUC. Interestingly, specific His was oxidized, which are located inside the capsid and thought to be located close to DNA. Doubly oxidation of His (+32) by D65 light stress is same as antibody as we reported in 2014 (https://lnkd.in/gT62RBBx).

Want to learn more about our next generation single cell GEM-X technology? Join us for this webinar (Feb 28th) to understand why these new products are so exciting!

This was a really easy one! Over 75 % of voters caught our cheeky little lie! Although the scFv antibody was the first format to be displayed on the surface of the phage in 1990, other antibody formats such as Fab and VHH have been reported to be displayed. The phage display technology stands as a powerful tool for antibody discovery. Using this technology, FJB has generated over 4000 phage display libraries from a combination of naïve, immunized, and synthetic repertoires. Learn more at: https://lnkd.in/d25cqzb5

The identification and selection of optimal clones that express high levels of a desired antibody is a critical and time-consuming step in the antibody discovery process. Learn how CellCelector significantly accelerates the process, compared to conventional techniques. #antibodydiscovery #lifescience #cellcelector

In this example, Marc Davies, PhD at Leucid Bio shows how the Omni Pro 12 captures the kinetic response of CAR T cells during re-stimulation assays—highlighting how real-time, continuous data offers deeper insights compared to conventional endpoint assays. To learn more about how regular monitoring of your assay with the Omni Pro 12 can elevate your research, be sure to watch our on-demand webinar via 🔗 https://bit.ly/3OMNwuW #CellTherapy #ImmunoOncology #OmniPro12 #LiveCellImaging 

It's not too late to register for our webinar tomorrow (Sept. 5) with Molecular Instruments! Join us to learn about the benefits of HCR™ RNA-ISH assays and #HALOimageAnalysis workflows, with live demos of HALO analysis workflows for brightfield and fluorescent images. Learn more and register: https://lnkd.in/g6N5g-PT #DigitalPathology #HCRimaging #OnlyWithHCR #InSituHybridization #TissueAnalysis #ImageAnalysis #IndicaLabs

From MBoC Evidence for novel mechanisms that control cell cycle entry and cell size It has been thought that transcription of late G1 phase cyclins is the critical molecular event that initiates cell cycle entry. New tests challenge this model and suggest surprising new mechanisms for control of cell cycle entry and cell size. https://lnkd.in/g7EBiGv9